Secondary antibody detected epitope and preparation of same
    5.
    发明授权
    Secondary antibody detected epitope and preparation of same 有权
    二抗检测表位及其制备方法

    公开(公告)号:US09458243B2

    公开(公告)日:2016-10-04

    申请号:US14534174

    申请日:2014-11-06

    Abstract: A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species.

    Abstract translation: 一种制备二抗检测蛋白质标签的表位的方法,包括:构建表达载体,其包含用于编码第二抗体检测的蛋白质标签的核苷酸序列,所述核苷酸序列包含至少一个选自至少一个第一抗体的表位,所述表位被相应的 二抗; 在宿主细胞中表达载体; 并获得在宿主细胞中表达的二抗检测蛋白质标签。 此外,构建蛋白质分子量标记梯的方法,包括构建多个具有不同分子量的重组蛋白质标签,其中每个重组蛋白质标签包含一抗的至少一个表位。 此外,二次抗体检测的蛋白质标签包含至少两个选自至少两种不同物种的一抗的表位的肽序列。

    ANTIBODY LOCKER FOR THE INACTIVATION OF PROTEIN DRUG
    10.
    发明申请
    ANTIBODY LOCKER FOR THE INACTIVATION OF PROTEIN DRUG 审中-公开
    用于灭活蛋白质药物的抗体锁

    公开(公告)号:US20160185875A1

    公开(公告)日:2016-06-30

    申请号:US14893509

    申请日:2014-05-28

    Abstract: Disclosed herein is a hinge antibody capable of being selectively activated in a target cell or tissue to treat a condition therein. The hinge antibody includes a functional antibody, two inhibitory domains and four cleavable linkers. The functional antibody is capable of treating the condition in an activated state, and has two light chains and two heavy chains. Each inhibitory domain includes a hinge domain of an immunoglobulin and consists of two peptide arms. Each cleavable linker includes a peptide substrate cleavable by an enzyme specifically or highly expressed in the target cell or tissue, and connects one of the peptide arms of the inhibitory domains to the N-terminal of one of the light chains and heavy chains of the functional antibody. Also disclosed herein are methods for preparing and using this hinge antibody.

    Abstract translation: 本文公开了能够在靶细胞或组织中选择性活化以治疗其中的病症的铰链抗体。 铰链抗体包括功能性抗体,两个抑制结构域和四个可切割接头。 功能性抗体能够处于活化状态,具有两条轻链和两条重链。 每个抑制结构域包括免疫球蛋白的铰链结构域并由两个肽臂组成。 每个可切割接头包括可以通过在靶细胞或组织中特异性或高度表达的酶可切割的肽底物,并将抑制结构域的一个肽臂连接到功能性的轻链和重链之一的N-末端 抗体。 本文还公开了制备和使用该铰链抗体的方法。

Patent Agency Ranking